| Ytd | 1.46% | |
| 1y | 37.73% |
| Open | 31.44 | Prev Close | 29.83 | Low | 30.92 | High | 31.79 | Mkt Cap | 19.19B |
| Vol | 3.50M | Avg Vol | 2.00M | EPS | 1.33 | P/E | 23.55 | Forward P/E | 17.18 |
| Beta | 0.69 | Short Ratio | 4.95 | Inst. Own | 13.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 27.07 | 200-d Avg | 29.04 | 1yr Est | 36.92 |
GMAB News
Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript
Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its
Avidity Partners Management LP reduced its stake in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 45.7%
Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NY
Genmab has underperformed so far this year despite strong commercial performance and largely positiv
Wall Street lit up Tuesday with massive earnings beats and a crypto surge, but Wednesday morning fut
Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, back
Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituxima
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Co
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 tria
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label
The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met th
Company Announcement Topline results from Phase 3 EPCORE ® DLBCL-4 evaluating epcoritamab in combin
Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase it
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 202
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcorita
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two st
Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial sho
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today
On Wednesday, 807 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Monday